Pharmafile Logo

News and Press Releases

Asymchem Secures Former Pfizer Sandwich, UK, Development and API Pilot Plant Manufacturing Facilities

21 May 2024 -- Teda Tianjin, P R China -- Asymchem Laboratories announced today that it will operate the former Pfizer UK small molecule API pilot plant and part of...

Category: BioManufacturing, Pharmaceutical
Posted: May 21, 2024

Asymchem
inquiry@asymchem.com
Asymchem Laboratories (Tianjin) Co., Ltd No. 6 Dongting 3rd Avenue, TEDA Tianjin, 300457, P.R. China

Over a thousand people with multiple myeloma may be eligible for treatment with Nexpovio▼ (selinexor) following NICE recommendation addressing ‘significant unmet need’ for this incurable blood cancer

NEXPOVIO has been recommended for use in the NHS, offering the opportunity to improve patient outcomes in this challenging and complex cancer NEXPOVIO has the potential to address significant treatment...

Category: Biotechnology, Pharmaceutical
Posted: April 22, 2024

Menarini
Menarini House, Mercury Park, Wycombe Lane, Wooburn Green, High Wycombe, HP10 0HH

Veklury (remdesivir) recommended by NICE for treatment of COVID-19 in vulnerable adults and children

Remdesivir is the first antiviral treatment recommended by NICE to treat eligible children, including those with a high risk of serious illness from COVID-19 This decision secures long-term access to...

Category: Pharmaceutical
Posted: April 9, 2024

Gilead Sciences, Inc

GSK’s Jemperli▼ (dostarlimab) is accepted for use within NHS Scotland, in line with its licence, in eligible endometrial cancer patients in first line setting

Clinicians in Scotland will now be able to use dostarlimab in combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced...

Category: Pharmaceutical
Posted: April 8, 2024

Scottish Medicines Consortium (SMC) accepts Camzyos▼(mavacamten) for use on the NHS as an adjunct treatment option for adults with symptomatic obstructive hypertrophic cardiomyopathy

Mavacamten has been accepted for use within NHS Scotland for the treatment of symptomatic(New York Heart Association, NYHA, class II to III) obstructive hypertrophic cardiomyopathy(HCM) in adult patients. HCM is...

Category: Pharmaceutical
Posted: April 8, 2024

Bristol Myers Squibb (BMS)
medical.information@bms.com
ARC Uxbridge Sanderson Road New Denham Denham Buckinghamshire UB8 1DH

Headlands Research Announces Fifth Research Site under Partnership with Pfizer to Improve Diversity in Clinical Trials

Headlands Research Orlando satisfies the organisations’ commitment to create multiple research sites aimed at increasing health equity in clinical research 28 March 2024 -- California, US -- Headlands Research, a...

Category: Clinical Trials
Posted: April 2, 2024

Headlands Research
130 John F Kennedy Dr STE 203 Lake Worth, FL 33462

Jemperli (dostarlimab) becomes the first immunotherapy treatment to receive NICE recommendation for use, in line with its license, in eligible endometrial cancer patients in first line setting

This final draft guidance recommends the use of dostarlimab in combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or...

Category: Clinical Trials, Drug Discovery
Posted: March 5, 2024

GSK
980 Great West Rd, London TW8 9GS

NICE has issued guidance for GSK’s Omjjara (momelotinib) as a treatment option for disease-related splenomegaly or symptoms in adult myelofibrosis patients with moderate to severe anaemia

Myelofibrosis is a rare blood cancer that can result in the progressive scarring of bone marrow (fibrosis), impairing its normal function There are approximately 1,970 people living with myelofibrosis across...

Category: Clinical Trials
Posted: February 15, 2024

GSK
980 Great West Rd, London TW8 9GS

NICE Recommends Lilly’s Mirikizumab (OMVOH) for the Treatment of Eligible Adults with Moderately to Severely Active Ulcerative Colitis.

22 September 2023 -- Basingstoke, UK -- Eli Lilly and Company announced today that the National Institute for Health and Care Excellence (NICE) have recommended mirikizumab for the treatment of...

Category: Pharmaceutical
Posted: September 22, 2023

Eli Lilly
ukpublicaffairs@lilly.com
450 Kendall Street Cambridge, MA 02142